Corvus outlines soquelitinib milestones with PTCL futility analysis in Q1 2027 and AD topline data in Q3 2027 — See source for full details.
$CRVS
Price history, market instrument context, member research, and related headlines in one place.
CRVS key statistics
NasdaqGMUSD
52-week range
$6.3917%$26.95
Latest session $9.36–$10.07Corvus Pharmaceuticals, Inc. (CRVS) is a stock instrument quoted on NasdaqGM in USD. The most recently published price is $9.85, up $0.47 (5.01%) from the previous close of $9.38. It has traded between $9.36 and $10.07 in the latest session. Over the past year it has ranged from $6.39 to $26.95, leaving it in the lower quarter of its 52-week range (17%). Reported volume for the session was 1M. Figures are the latest published by the exchange feed and are not a recommendation.
Primary market bars from Yahoo Finance · Extended-hours prints appear when supplied by the venue · Interactive charts powered by TradingView Lightweight Charts™ · Not a recommendation
Source-linked intelligence
Related news
Loading $CRVS research…